Clinical Trials for Sarcoma

An Open-Label, Multicenter, Phase 2 Study With Safety Lead-In of Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab in Patients With Angiosarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with unresectable locally advanced or metastatic cutaneous angiosarcoma, injectable lesions, and progression after immunotherapy and first-line taxane- or anthracycline-based chemotherapy receive intratumoral vusolimogene oderparepvec (VO) plus pembrolizumab. VO is an engineered oncolytic herpesvirus that promotes tumor-cell destruction and immune activation; pembrolizumab blocks PD-1.

ClinicalTrials.gov ID: NCT06898970

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic alveolar soft part sarcoma, leiomyosarcoma, or synovial sarcoma receive oral anlotinib, a multikinase inhibitor targeting VEGFR, FGFR, PDGFR, and c-Kit. The alveolar soft part sarcoma cohort is single-arm; leiomyosarcoma and synovial sarcoma cohorts compare anlotinib with dacarbazine or, in a separate leiomyosarcoma cohort, placebo.

ClinicalTrials.gov ID: NCT03016819

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible adults have previously treated, locally advanced or metastatic SMARCB1-deficient renal medullary carcinoma or epithelioid sarcoma with MUC16 expression; unclassified renal carcinoma with a medullary phenotype is also eligible. Treatment is ubamatamab, an investigational MUC16×CD3 bispecific antibody that recruits T cells to tumors, alone or with the PD-1 inhibitor cemiplimab.

ClinicalTrials.gov ID: NCT06444880

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable locally advanced, recurrent, or metastatic liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma and an injectable tumor are randomized to intratumoral INT230-6 or investigator-selected pazopanib, trabectedin, or eribulin. INT230-6 combines cisplatin and vinblastine with SHAO, a penetration enhancer intended to disperse the cytotoxic drugs through tumor tissue.

ClinicalTrials.gov ID: NCT06263231

A Phase II Study of sEphB4-HSA in Kaposi Sarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with biopsy-confirmed cutaneous Kaposi sarcoma, with or without visceral involvement, receive IV sEphB4-HSA every two weeks; prior treatment is permitted, and patients with HIV must be on stable antiretroviral therapy. This investigational fusion protein binds ephrin-B2 to disrupt EphB4–ephrin-B2 signaling involved in angiogenesis; patients needing immediate cytotoxic therapy are excluded.

ClinicalTrials.gov ID: NCT03993106

An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory advanced solid tumors, including sarcoma, who have an injectable tumor lesion and ECOG 0–1 receive intratumoral AdAPT-001 alone or with an investigator-selected checkpoint inhibitor. AdAPT-001 is an oncolytic adenovirus designed to lyse cancer cells and produce a TGF-β trap to counter tumor-associated immune suppression.

ClinicalTrials.gov ID: NCT04673942

A Dose Escalation Study Using Eflornithine (DFMO) and AMXT 1501 Followed by a Randomized Controlled Trial of DFMO With or Without AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls patients diagnosed by age 21 with relapsed or refractory high-risk neuroblastoma, ETMR, ATRT, Ewing sarcoma, or osteosarcoma, or newly diagnosed DIPG after radiation. Patients receive oral eflornithine (DFMO), an ornithine decarboxylase inhibitor that blocks polyamine synthesis, with or without AMXT 1501, an investigational polyamine-uptake inhibitor; the neuroblastoma cohort is randomized between the two regimens.

ClinicalTrials.gov ID: NCT06465199

A Phase I Trial of Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic leiomyosarcoma or adipocytic sarcoma progressing after 1–4 prior therapies receive oral zanzalintinib plus intravenous eribulin. Zanzalintinib is an investigational multikinase inhibitor targeting VEGFR2, MET, TYRO3, AXL, and MER.

ClinicalTrials.gov ID: NCT06957431

A Phase II Trial to Assess the Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor Patients With Homozygous MTAP Deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Patients aged 12 years or older with unresectable, locally advanced or metastatic malignant peripheral nerve sheath tumors and confirmed homozygous MTAP deletion receive oral BMS-986504. This investigational MTA-cooperative PRMT5 inhibitor is designed to exploit the synthetic-lethal vulnerability of MTAP-deleted tumors.

ClinicalTrials.gov ID: NCT07549022

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic or unresectable RB1-negative leiomyosarcoma that has progressed after at least one systemic therapy receive oral REC-617, a selective CDK7 inhibitor, at 10 mg once daily.

ClinicalTrials.gov ID: NCT07633756